Overview

Clofarabine Bone Marrow Cytoreduction

Status:
Completed

Trial end date:
2012-09-01

Target enrollment:

Participant gender:

Summary

For relapsed and refractory leukemia patients induction chemotherapy prior to initiating a conditioning regimen will decrease residual leukemia (as measured by bone marrow leukemia blast percentage) at the time of HCT. This should lead to reduced relapse while still maintaining low transplant related mortality.

Phase:

Phase 2

Details

Lead Sponsor:

University of Chicago

Collaborator:

Genzyme, a Sanofi Company

Treatments:

Clofarabine